Imatinib and nilotinib (Novartis Pharmaceuticals) are protein tyrosine kinase inhibitors whose main targets include platelet-derived growth factor (PDGF) receptor (PDGFR), discoidin domain receptor, stem cell factor receptor (KIT), Abelson kinase (ABL) and the oncogenic breakpoint cluster region-Abelson kinase (BCR-ABL) that causes chronic myeloid leukemia [12]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.